Groowe Groowe / Newsroom / NVS
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

NVS News

Novartis AG

Kenai Therapeutics Appoints Blake Arnold, CFA, as Chief Business Officer

prnewswire.com
NVS BAX

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

globenewswire.com
NVS

Nikon Expands Popular Monarch and Prostaff Binocular Lines

accessnewswire.com
NVS

Ivim Health GLP-1 Weight Loss: Cost Breakdown, Clinical Data, and What They Don't Tell You (2026)

accessnewswire.com
NVS LLY

More Than 30 Million Americans Living with Rare Diseases

prnewswire.com
AMGN SNY AGIO ASND DVA INCY NVS PFE REGN UCB

Chemotherapy Induced Peripheral Neuropathy (CIPN) Treatment Market Report 2026-2032: Revenues to Grow by $750M at 8.64% CAGR

globenewswire.com
ABBV AMGN PFE BMY MRK REGN SNY TAK NVS GSK HRTX

Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)

globenewswire.com
NVS

Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More

globenewswire.com
GILD NVS BMY ORGN

Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D

businesswire.com
NVS BMY AMGN

ZERO Prostate Cancer Announces 2026 Prostate Cancer Summit and Veterans Action Convening to Improve Care and Outcomes for Veterans

prnewswire.com
PFE NVS AZN